Edition:
United States

Celldex Therapeutics Inc (CLDX.A)

CLDX.A on American Stock Exchange

2.35USD
10 Jul 2019
Change (% chg)

-- (--)
Prev Close
$2.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
348
52-wk High
$9.00
52-wk Low
$2.41

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Reports Q4 Loss Per Share $0.03
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Celldex Therapeutics Inc ::CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.03.CELLDEX THERAPEUTICS - ANTICIPATE TOPLINE PRIMARY ENDPOINT DATA FROM METRIC STUDY OF GLEMBATUMUMAB VEDOTIN WILL BE AVAILABLE IN Q2 OF 2018.Q4 REVENUE $3.5 MILLION VERSUS $1.9 MILLION.  Full Article

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Q2 loss per share $0.23.Q2 revenue $3.8 million versus $2.7 million.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Celldex Therapeutics Q2 loss per share $0.23
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Celldex Therapeutics Inc :Celldex reports second quarter 2017 results.Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million.Q2 loss per share $0.23.Q2 revenue view $1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article